SCYX SCYNEXIS Inc Forecast, Technical & Fundamental Analysis
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs... Show more
SCYX is expected to report earnings to fall 79.37% to -69 cents per share on August 17
Q2'26
Est.
$-0.69
Q1'26
Missed
by $2.32
Q4'25
Beat
by $0.12
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.06
The last earnings report on May 11 showed earnings per share of -335 cents, missing the estimate of -103 cents. With 62.10K shares outstanding, the current market capitalization sits at 40.42M.
A.I. Advisor
published General Information
General Information
a company which engages in discovery, development and commercialization of novel anti infectives
A.I.dvisor tells us that SCYX and ACET have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ACET's prices will move in lockstep.
SCYX's RSI Indicator ascends from oversold territory
The RSI Indicator for SCYX moved out of oversold territory on June 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SCYX just turned positive on June 23, 2026. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SCYX advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .
SCYX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for SCYX moved below the 200-day moving average on June 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SCYX entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.913) is normal, around the industry mean (79.619). P/E Ratio (0.905) is within average values for comparable stocks, (97.708). SCYX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.175) is also within normal values, averaging (96.435).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
